Can a person with lung nodules and mild asthma receive the pneumonia vaccine?

Generally, individuals with pulmonary nodules and mild asthma can receive the pneumonia vaccine when their condition is stable, but vaccination should be postponed during an acute asthma attack. If in doubt, it is recommended to consult a doctor in advance for evaluation. Detailed analysis is as follows:

If the pulmonary nodule is benign and asymptomatic, and asthma is well-controlled—without acute exacerbations in the past three months—and lung function is stable, receiving the pneumonia vaccine can reduce the risk of pulmonary infection without worsening the underlying conditions, thus meeting the basic criteria for vaccination.

However, if asthma is in an acute exacerbation phase with symptoms such as wheezing, coughing, or chest tightness, or if the nature of the pulmonary nodule is undetermined or there are signs of infection, vaccination may trigger worsening asthma or impair the vaccine's effectiveness. In these cases, primary conditions should be treated first, and vaccination considered only after the condition has stabilized.

Prior to vaccination, patients should inform their doctor about the results of pulmonary nodule evaluations and asthma control status, and complete relevant assessments such as lung function tests. After vaccination, a 30-minute observation period is recommended, with close monitoring of respiratory status. Regular asthma management and routine follow-up imaging for pulmonary nodules are essential to ensure both vaccination safety and overall disease stability.